Drug resistance is the main reason for AML relapse and poor prognosis and, since miR-181b can increase AML drug sensitivity through down-regulation of HMGB1 and MCL-1, it is not surprising that miR-181b was down-regulated in relapsed and refractory AML patients [104]. This evidence concerns the gene MCL1 and acute myeloid leukemia.